Revenue Update on Nabriva Therapeutics AG – ADR(NASDAQ:NBRV)

Nabriva Therapeutics AG – ADR(NASDAQ:NBRV) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 9, 2016. Company reported revenue of $899.00K. Analysts estimated a revenue of $990.00K. Earnings per share were $-9.03. Analysts had estimated an EPS of $-6.25.

Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin a Phase Two plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP) and BC-7013 a Phase One topical pleuromutilin treatment for Gram-positive infections including uncomplicated skin and skin structure infections (uSSSSIs). In addition the Company has completed a Phase Two clinical trial for acute bacterial skin and skin structure infections (ABSSSI) and in Discovery Phase development of extended-spectrum pleuromutilins (ESPs) a pleuromutilin compound that treats Gram-negative bacteria. The Company is a spin-off of Sandoz GmbH and receives investment from HBM Healthcare Investments Novartis Venture Fund Omega Funds OrbiMed Healthcare Fund Management Phase4 Partners Vivo Capital and the Wellcome Trust.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *